QTc Interval Screening in an Opioid Treatment Program
Methadone is highly effective for opioid dependency, but it is associated with Torsade de pointes. Although electrocardiography (ECG) has been proposed, its utility is uncertain, because an ECG-based intervention has not been described. An ECG-based cardiac safety program in methadone maintenance pa...
Gespeichert in:
| Veröffentlicht in: | The American journal of cardiology 2013-10, Vol.112 (7), p.1013-1018 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1018 |
|---|---|
| container_issue | 7 |
| container_start_page | 1013 |
| container_title | The American journal of cardiology |
| container_volume | 112 |
| creator | Katz, David F., MD Sun, Jun, MS Khatri, Vaishali, MPH Kao, David, MD Bucher-Bartelson, Becki, PhD Traut, Carol, MD Lundin-Martinez, John, BSN, JD Goodman, Michael Mehler, Philip S., MD Krantz, Mori J., MD |
| description | Methadone is highly effective for opioid dependency, but it is associated with Torsade de pointes. Although electrocardiography (ECG) has been proposed, its utility is uncertain, because an ECG-based intervention has not been described. An ECG-based cardiac safety program in methadone maintenance patients was evaluated in a single opioid treatment program from September 1, 2009, to August 31, 2011, in the United States. Time from pretreatment to repeat ECG in new entrants was assessed. The proportion with marked rate-corrected QT (QTc) interval prolongation (>500 ms) and the effect of the intervention on the QTc interval in this group were evaluated. Multivariate predictors of QTc interval change were assessed using a mixed-effects model. Of 531 new entrants, 436 (82%) underwent ≥1 electrocardiographic assessment, and 186 (35%) underwent pretreatment ECG. Median time to follow-up ECG was 43 days but decreased over time (p 500 ms, the mean QTc interval from peak to final ECG decreased significantly (−55.5 ms, 95% confidence interval −77.0 to −33.9, p = 0.001), and 12 of 21 (57.1%) decreased to lower than the 500-ms threshold. In new entrants with serial ECG, only methadone dose (p = 0.009) and pretreatment QTc interval (p |
| doi_str_mv | 10.1016/j.amjcard.2013.05.037 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4361084</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002914913012356</els_id><sourcerecordid>3073690591</sourcerecordid><originalsourceid>FETCH-LOGICAL-c550t-49a261813878b533ba66d4f030a0d8a782ddf68928488a5ec43733e4744355663</originalsourceid><addsrcrecordid>eNqFkU9vEzEQxS0EoqHwEUArcd5l7LG93ksRqoBWqlRQw9lybCd42fUGexOp3x5HScufC6eRNW_ePP-GkNcUGgpUvusbM_bWJNcwoNiAaADbJ2RBVdvVtKP4lCwAgNUd5d0ZeZFzX56UCvmcnDFUDEQLCyK-Lm11HWef9mao7mzyPoa4qUKsTKxut2EKrlomb-bRx7n6kqZNMuNL8mxthuxfneo5-fbp4_Lyqr65_Xx9-eGmtkLAXPPOMEkVRdWqlUBcGSkdXwOCAadMq5hza6k6prhSRnjLsUX0vOUchZASz8nF0Xe7W43e2RIhmUFvUxhNuteTCfrvTgzf9Wbaa46SguLF4O3JIE0_dz7Pup92KZbMmnJEaFGyrqjEUWXTlHPy68cNFPSBtu71ibY-0NYgdKFd5t78Ge9x6gFvEbw_CnyBtA8-6WyDj9a7kLydtZvCf1dc_ONghxCDNcMPf-_z79_ozDTou8PJDxenCJShkPgLnc6l3w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1433073629</pqid></control><display><type>article</type><title>QTc Interval Screening in an Opioid Treatment Program</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Katz, David F., MD ; Sun, Jun, MS ; Khatri, Vaishali, MPH ; Kao, David, MD ; Bucher-Bartelson, Becki, PhD ; Traut, Carol, MD ; Lundin-Martinez, John, BSN, JD ; Goodman, Michael ; Mehler, Philip S., MD ; Krantz, Mori J., MD</creator><creatorcontrib>Katz, David F., MD ; Sun, Jun, MS ; Khatri, Vaishali, MPH ; Kao, David, MD ; Bucher-Bartelson, Becki, PhD ; Traut, Carol, MD ; Lundin-Martinez, John, BSN, JD ; Goodman, Michael ; Mehler, Philip S., MD ; Krantz, Mori J., MD</creatorcontrib><description>Methadone is highly effective for opioid dependency, but it is associated with Torsade de pointes. Although electrocardiography (ECG) has been proposed, its utility is uncertain, because an ECG-based intervention has not been described. An ECG-based cardiac safety program in methadone maintenance patients was evaluated in a single opioid treatment program from September 1, 2009, to August 31, 2011, in the United States. Time from pretreatment to repeat ECG in new entrants was assessed. The proportion with marked rate-corrected QT (QTc) interval prolongation (>500 ms) and the effect of the intervention on the QTc interval in this group were evaluated. Multivariate predictors of QTc interval change were assessed using a mixed-effects model. Of 531 new entrants, 436 (82%) underwent ≥1 electrocardiographic assessment, and 186 (35%) underwent pretreatment ECG. Median time to follow-up ECG was 43 days but decreased over time (p <0.0001). In 21 patients with QTc intervals >500 ms, the mean QTc interval from peak to final ECG decreased significantly (−55.5 ms, 95% confidence interval −77.0 to −33.9, p = 0.001), and 12 of 21 (57.1%) decreased to lower than the 500-ms threshold. In new entrants with serial ECG, only methadone dose (p = 0.009) and pretreatment QTc interval (p <0.0001) were associated with the magnitude of QTc interval change. In conclusion, this study suggests that the implementation of an ECG-based intervention in methadone maintenance can decrease the QTc interval in high-risk patients; clinical characteristics alone were inadequate to identify patients in need of electrocardiographic screening.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/j.amjcard.2013.05.037</identifier><identifier>PMID: 23820570</identifier><identifier>CODEN: AJCDAG</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Analgesics, Opioid - adverse effects ; Arrhythmias, Cardiac - chemically induced ; Arrhythmias, Cardiac - diagnosis ; Cardiovascular ; Drug therapy ; Electrocardiography ; Female ; Hospitals ; Humans ; Male ; Mass Screening ; Methadone ; Methadone - adverse effects ; Middle Aged ; Mortality ; Opiate Substitution Treatment - adverse effects ; Opioid-Related Disorders - drug therapy ; Program Evaluation ; Risk Assessment ; Schizophrenia</subject><ispartof>The American journal of cardiology, 2013-10, Vol.112 (7), p.1013-1018</ispartof><rights>Elsevier Inc.</rights><rights>2013 Elsevier Inc.</rights><rights>Copyright © 2013 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Oct 1, 2013</rights><rights>2013 Excerpta Medica, Inc. All rights reserved. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c550t-49a261813878b533ba66d4f030a0d8a782ddf68928488a5ec43733e4744355663</citedby><cites>FETCH-LOGICAL-c550t-49a261813878b533ba66d4f030a0d8a782ddf68928488a5ec43733e4744355663</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1433073629?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995,64385,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23820570$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Katz, David F., MD</creatorcontrib><creatorcontrib>Sun, Jun, MS</creatorcontrib><creatorcontrib>Khatri, Vaishali, MPH</creatorcontrib><creatorcontrib>Kao, David, MD</creatorcontrib><creatorcontrib>Bucher-Bartelson, Becki, PhD</creatorcontrib><creatorcontrib>Traut, Carol, MD</creatorcontrib><creatorcontrib>Lundin-Martinez, John, BSN, JD</creatorcontrib><creatorcontrib>Goodman, Michael</creatorcontrib><creatorcontrib>Mehler, Philip S., MD</creatorcontrib><creatorcontrib>Krantz, Mori J., MD</creatorcontrib><title>QTc Interval Screening in an Opioid Treatment Program</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>Methadone is highly effective for opioid dependency, but it is associated with Torsade de pointes. Although electrocardiography (ECG) has been proposed, its utility is uncertain, because an ECG-based intervention has not been described. An ECG-based cardiac safety program in methadone maintenance patients was evaluated in a single opioid treatment program from September 1, 2009, to August 31, 2011, in the United States. Time from pretreatment to repeat ECG in new entrants was assessed. The proportion with marked rate-corrected QT (QTc) interval prolongation (>500 ms) and the effect of the intervention on the QTc interval in this group were evaluated. Multivariate predictors of QTc interval change were assessed using a mixed-effects model. Of 531 new entrants, 436 (82%) underwent ≥1 electrocardiographic assessment, and 186 (35%) underwent pretreatment ECG. Median time to follow-up ECG was 43 days but decreased over time (p <0.0001). In 21 patients with QTc intervals >500 ms, the mean QTc interval from peak to final ECG decreased significantly (−55.5 ms, 95% confidence interval −77.0 to −33.9, p = 0.001), and 12 of 21 (57.1%) decreased to lower than the 500-ms threshold. In new entrants with serial ECG, only methadone dose (p = 0.009) and pretreatment QTc interval (p <0.0001) were associated with the magnitude of QTc interval change. In conclusion, this study suggests that the implementation of an ECG-based intervention in methadone maintenance can decrease the QTc interval in high-risk patients; clinical characteristics alone were inadequate to identify patients in need of electrocardiographic screening.</description><subject>Adult</subject><subject>Analgesics, Opioid - adverse effects</subject><subject>Arrhythmias, Cardiac - chemically induced</subject><subject>Arrhythmias, Cardiac - diagnosis</subject><subject>Cardiovascular</subject><subject>Drug therapy</subject><subject>Electrocardiography</subject><subject>Female</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Male</subject><subject>Mass Screening</subject><subject>Methadone</subject><subject>Methadone - adverse effects</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Opiate Substitution Treatment - adverse effects</subject><subject>Opioid-Related Disorders - drug therapy</subject><subject>Program Evaluation</subject><subject>Risk Assessment</subject><subject>Schizophrenia</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkU9vEzEQxS0EoqHwEUArcd5l7LG93ksRqoBWqlRQw9lybCd42fUGexOp3x5HScufC6eRNW_ePP-GkNcUGgpUvusbM_bWJNcwoNiAaADbJ2RBVdvVtKP4lCwAgNUd5d0ZeZFzX56UCvmcnDFUDEQLCyK-Lm11HWef9mao7mzyPoa4qUKsTKxut2EKrlomb-bRx7n6kqZNMuNL8mxthuxfneo5-fbp4_Lyqr65_Xx9-eGmtkLAXPPOMEkVRdWqlUBcGSkdXwOCAadMq5hza6k6prhSRnjLsUX0vOUchZASz8nF0Xe7W43e2RIhmUFvUxhNuteTCfrvTgzf9Wbaa46SguLF4O3JIE0_dz7Pup92KZbMmnJEaFGyrqjEUWXTlHPy68cNFPSBtu71ibY-0NYgdKFd5t78Ge9x6gFvEbw_CnyBtA8-6WyDj9a7kLydtZvCf1dc_ONghxCDNcMPf-_z79_ozDTou8PJDxenCJShkPgLnc6l3w</recordid><startdate>20131001</startdate><enddate>20131001</enddate><creator>Katz, David F., MD</creator><creator>Sun, Jun, MS</creator><creator>Khatri, Vaishali, MPH</creator><creator>Kao, David, MD</creator><creator>Bucher-Bartelson, Becki, PhD</creator><creator>Traut, Carol, MD</creator><creator>Lundin-Martinez, John, BSN, JD</creator><creator>Goodman, Michael</creator><creator>Mehler, Philip S., MD</creator><creator>Krantz, Mori J., MD</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7Z</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>20131001</creationdate><title>QTc Interval Screening in an Opioid Treatment Program</title><author>Katz, David F., MD ; Sun, Jun, MS ; Khatri, Vaishali, MPH ; Kao, David, MD ; Bucher-Bartelson, Becki, PhD ; Traut, Carol, MD ; Lundin-Martinez, John, BSN, JD ; Goodman, Michael ; Mehler, Philip S., MD ; Krantz, Mori J., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c550t-49a261813878b533ba66d4f030a0d8a782ddf68928488a5ec43733e4744355663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Analgesics, Opioid - adverse effects</topic><topic>Arrhythmias, Cardiac - chemically induced</topic><topic>Arrhythmias, Cardiac - diagnosis</topic><topic>Cardiovascular</topic><topic>Drug therapy</topic><topic>Electrocardiography</topic><topic>Female</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Male</topic><topic>Mass Screening</topic><topic>Methadone</topic><topic>Methadone - adverse effects</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Opiate Substitution Treatment - adverse effects</topic><topic>Opioid-Related Disorders - drug therapy</topic><topic>Program Evaluation</topic><topic>Risk Assessment</topic><topic>Schizophrenia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Katz, David F., MD</creatorcontrib><creatorcontrib>Sun, Jun, MS</creatorcontrib><creatorcontrib>Khatri, Vaishali, MPH</creatorcontrib><creatorcontrib>Kao, David, MD</creatorcontrib><creatorcontrib>Bucher-Bartelson, Becki, PhD</creatorcontrib><creatorcontrib>Traut, Carol, MD</creatorcontrib><creatorcontrib>Lundin-Martinez, John, BSN, JD</creatorcontrib><creatorcontrib>Goodman, Michael</creatorcontrib><creatorcontrib>Mehler, Philip S., MD</creatorcontrib><creatorcontrib>Krantz, Mori J., MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Physical Education Index</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biochemistry Abstracts 1</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Katz, David F., MD</au><au>Sun, Jun, MS</au><au>Khatri, Vaishali, MPH</au><au>Kao, David, MD</au><au>Bucher-Bartelson, Becki, PhD</au><au>Traut, Carol, MD</au><au>Lundin-Martinez, John, BSN, JD</au><au>Goodman, Michael</au><au>Mehler, Philip S., MD</au><au>Krantz, Mori J., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>QTc Interval Screening in an Opioid Treatment Program</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>2013-10-01</date><risdate>2013</risdate><volume>112</volume><issue>7</issue><spage>1013</spage><epage>1018</epage><pages>1013-1018</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><coden>AJCDAG</coden><abstract>Methadone is highly effective for opioid dependency, but it is associated with Torsade de pointes. Although electrocardiography (ECG) has been proposed, its utility is uncertain, because an ECG-based intervention has not been described. An ECG-based cardiac safety program in methadone maintenance patients was evaluated in a single opioid treatment program from September 1, 2009, to August 31, 2011, in the United States. Time from pretreatment to repeat ECG in new entrants was assessed. The proportion with marked rate-corrected QT (QTc) interval prolongation (>500 ms) and the effect of the intervention on the QTc interval in this group were evaluated. Multivariate predictors of QTc interval change were assessed using a mixed-effects model. Of 531 new entrants, 436 (82%) underwent ≥1 electrocardiographic assessment, and 186 (35%) underwent pretreatment ECG. Median time to follow-up ECG was 43 days but decreased over time (p <0.0001). In 21 patients with QTc intervals >500 ms, the mean QTc interval from peak to final ECG decreased significantly (−55.5 ms, 95% confidence interval −77.0 to −33.9, p = 0.001), and 12 of 21 (57.1%) decreased to lower than the 500-ms threshold. In new entrants with serial ECG, only methadone dose (p = 0.009) and pretreatment QTc interval (p <0.0001) were associated with the magnitude of QTc interval change. In conclusion, this study suggests that the implementation of an ECG-based intervention in methadone maintenance can decrease the QTc interval in high-risk patients; clinical characteristics alone were inadequate to identify patients in need of electrocardiographic screening.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>23820570</pmid><doi>10.1016/j.amjcard.2013.05.037</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9149 |
| ispartof | The American journal of cardiology, 2013-10, Vol.112 (7), p.1013-1018 |
| issn | 0002-9149 1879-1913 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4361084 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
| subjects | Adult Analgesics, Opioid - adverse effects Arrhythmias, Cardiac - chemically induced Arrhythmias, Cardiac - diagnosis Cardiovascular Drug therapy Electrocardiography Female Hospitals Humans Male Mass Screening Methadone Methadone - adverse effects Middle Aged Mortality Opiate Substitution Treatment - adverse effects Opioid-Related Disorders - drug therapy Program Evaluation Risk Assessment Schizophrenia |
| title | QTc Interval Screening in an Opioid Treatment Program |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T08%3A22%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=QTc%20Interval%20Screening%20in%20an%20Opioid%20Treatment%20Program&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Katz,%20David%20F.,%20MD&rft.date=2013-10-01&rft.volume=112&rft.issue=7&rft.spage=1013&rft.epage=1018&rft.pages=1013-1018&rft.issn=0002-9149&rft.eissn=1879-1913&rft.coden=AJCDAG&rft_id=info:doi/10.1016/j.amjcard.2013.05.037&rft_dat=%3Cproquest_pubme%3E3073690591%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1433073629&rft_id=info:pmid/23820570&rft_els_id=S0002914913012356&rfr_iscdi=true |